Opendata, web and dolomites

MICROB-PREDICT SIGNED

MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MICROB-PREDICT project word cloud

Explore the words cloud of the MICROB-PREDICT project. It provides you a very rough idea of what is the project "MICROB-PREDICT" about.

connected    progression    stratify    body    assemble    aclf    enrich    metabolizes    leaders    interaction    host    acute    million    scientific    channel    axis    microbiome    specialists    deaths    cirrhosis    elpa    health    liver    world    personalize    respect    experts    tests    sites    care    understand    confounders    data    omics    first    12    signatures    alter    international    biomarkers    interactome    functionalities    chronic    collected    personalized    treatment    accurate    easl    patient    predict    hepatology    manner    samples    association    smartphone    visits    randomized    prediction    causes    technologies    shapes    excellence    holistic    drugs    microb    clinical    validate    point    stratification    sequential    decompensation    causally    powerful    gt    decompensated    cutting    tools    longitudinal    nanobiosensors    carries    person    determines    patients    individual    gut    edge    possibly    trial    communication    risk   

Project "MICROB-PREDICT" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) 

Organization address
address: TRAVESSERA DE GRACIA 11, 7TH FLOOR
city: BARCELONA
postcode: 8021
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 15˙000˙002 €
 EC max contribution 15˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) ES (BARCELONA) coordinator 2˙273˙400.00
2    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) participant 2˙021˙900.00
3    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 1˙246˙100.00
4    FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA ES (BELLATERRA (BARCELONA)) participant 1˙089˙400.00
5    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) participant 996˙000.00
6    ODENSE UNIVERSITETSHOSPITAL DK (ODENSE) participant 800˙000.00
7    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 648˙000.00
8    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 635˙000.00
9    INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT FR (PARIS CEDEX 07) participant 620˙000.00
10    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 620˙000.00
11    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 535˙000.00
12    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 500˙500.00
13    KING'S COLLEGE LONDON UK (LONDON) participant 500˙000.00
14    VAIOMER FR (LABEGE) participant 484˙000.00
15    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 460˙000.00
16    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 423˙500.00
17    DEBRECENI EGYETEM HU (DEBRECEN) participant 347˙000.00
18    BIOBYTE SOLUTIONS GMBH DE (Heidelberg) participant 290˙000.00
19    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 224˙000.00
20    UNIVERSITETET I OSLO NO (OSLO) participant 150˙000.00
21    EUROPEAN LIVER PATIENTS ASSOCIATION BE (BRUXELLES) participant 80˙000.00
22    EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER CH (ZURICH) participant 56˙200.00

Map

 Project objective

Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.

 Deliverables

List of deliverables.
Project brochure and professional templates Websites, patent fillings, videos etc. 2020-04-25 11:37:03
Go-online of the public project website Websites, patent fillings, videos etc. 2020-04-25 11:37:03

Take a look to the deliverables list in detail:  detailed list of MICROB-PREDICT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MICROB-PREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MICROB-PREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

ENDFLU (2020)

Evaluation of ratioNally Designed Influenza vaccines

Read More